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Abstract 
The current treatment for hepatitis C virus (HCV) infection – combination therapy 
with pegylated interferon and ribavirin – elicits sustained responses in only ~50% of 
the patients treated. Greater cumulative exposure to ribavirin increases response to 
interferon-ribavirin combination therapy. A key limitation, however, is the toxic side-
effect of ribavirin, hemolytic anemia, which often necessitates a reduction of ribavirin 
dosage and compromises treatment response. Maximizing treatment response thus 
requires striking a balance between the antiviral and hemolytic activities of ribavirin.  
Current models of viral kinetics describe the enhancement of treatment response due 
to ribavirin. Ribavirin-induced anemia, however, remains poorly understood and 
precludes rational optimization of combination therapy.  
Here, we develop a new mathematical model of the population dynamics of 
erythrocytes that quantitatively describes ribavirin-induced anemia in HCV patients. 
Based on the assumption that ribavirin accumulation decreases erythrocyte lifespan in 
a dose-dependent manner, model predictions capture several independent 
experimental observations of the accumulation of ribavirin in erythrocytes and the 
resulting decline of hemoglobin in HCV patients undergoing combination therapy, 
estimate the reduced erythrocyte lifespan in patients and describe inter-patient 
variations in the severity of ribavirin-induced anemia. Further, model predictions 
estimate the threshold ribavirin exposure beyond which anemia becomes intolerable 
and suggest guidelines for the usage of growth hormones. A small fraction of the 
population (~30%) with polymorphisms in the ITPA gene shows protection from 
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ribavirin-induced anemia. The optimum dosage of ribavirin that can be tolerated is 
then dependent on the ITPA polymorphisms. Coupled with a previous population 
pharmacokinetic study, our model yields a facile formula for estimating the optimum 
dosage given a patient’s weight, creatinine clearance, pretreatment hemoglobin levels, 
and ITPA polymorphism. The reduced lifespan we predict is in agreement with 
independent measurements from breath tests as well as estimates derived from in vitro 
studies of ATP depletion. The latter estimates also agree with the extent of ATP 
depletion due to ribavirin that we predict from a detailed analysis of the nucleoside 
metabolism in erythrocytes. 
Our model thus facilitates in conjunction with models of viral kinetics the rational 
identification of treatment protocols. Our formula for optimum dose presents an 
avenue for personalizing ribavirin dosage. By keeping anemia tolerable, the predicted 
optimal dosage may improve adherence, reduce the need for drug monitoring, and 
increase response rates.  
 
 
 
 
 
